|
Chỉ định và Liều dùng
Oral
Susceptible infections Adult: 6-12 g/day in 2 divided doses.
Child: 100 mg/kg/day. |
|
Chống chỉ định
Porphyria; severe renal or hepatic failure; blood disorders; hypersensitivity to sulfonamides; SLE. Pregnancy (prior to delivery). Lactation. Infants within 1-2 mth of birth.
|
|
Thận trọng
Adequate fluid intake is necessary to reduce the risk of crystalluria. Discontinue immediately if rash appears. Renal or hepatic impairment; asthma or history of allergy; elderly. G6PD deficiency.
|
|
Tác dụng không mong muốn
GI effects, hypersensitivity reactions, nephrotoxic reactions, hepatic disorders, CV effects, hypoglycaemia, hypothyroidism, neurological reactions. Pseudomembranous colitis; jaundice and kernicterus in the newborn.
Potentially Fatal: Toxic epidermal necrolysis, Stevens-Johnson syndrome, anaphylaxis, blood dyscrasias. |
|
Tương tác
Action antagonised by PABA and procaine group of local anaesthetics. Potentiates oral anticoagulants, methotrexate and phenytoin. Increased risk of crystalluria with compounds that render urine acidic.
|
|
Ảnh hưởng đến kết quả xét nghiệm
May interfere with diagnostic tests for urea, creatinine and urobilinogen.
|
|
Tác dụng
Description:
Mechanism of Action: Sulfaguanidine is a sulfonamide with properties similar to those of sulfamethoxazole. Sulfonamides have a similar structure to para-aminobenzoic acid (PABA) and interfere with the synthesis of nucleic acid in sensitive microorganisms by blocking the coversion of PABA to the co-enzyme dihydrofolic acid, a reduced form of folic acid. Their actions are primarily bacteriostatic, although bactericidal effects are exerted where concentrations of thymine are low in the surrounding medium. |
|
Phân loại MIMS
|
Đăng xuất
